StockData
AbbVie Inc. logo

AbbVie Inc. (ABBV) stock

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3090% above fair value
$294.55−0.48 (-0.16%)

Close on Nov 16, 2026Market cap $520.50BP/E 83.2Yield 2.26%

AbbVie r&d expenses

Research and development expenses are spending on new products and technology.

AbbVie's R&D Expenses for the twelve months ending Jun 30, 2026 was $9.71B, down 25.9% year over year. For fiscal 2025 it was $9.10B, down 28.9% from the year before. Over ten years it grew 7.8% a year on average. The highest annual figure on record is $12.79B in fiscal 2024.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$9.10B-28.9%
FY2024Dec 31, 2024$12.79B+66.7%
FY2023Dec 31, 2023$7.68B+17.9%
FY2022Dec 31, 2022$6.51B-6.0%
FY2021Dec 31, 2021$6.92B+8.5%
FY2020Dec 31, 2020$6.38B-0.4%
FY2019Dec 31, 2019$6.41B-38.0%
FY2018Dec 31, 2018$10.33B+106.3%
FY2017Dec 31, 2017$5.01B+14.2%
FY2016Dec 31, 2016$4.39B+2.3%
FY2015Dec 31, 2015$4.29B+30.0%
FY2014Dec 31, 2014$3.30B+15.5%
FY2013Dec 31, 2013$2.86B+2.8%
FY2012Dec 31, 2012$2.78B+6.1%
FY2011Dec 31, 2011$2.62B–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$2.34B+10.0%
Q1 FY2026Mar 31, 2026$2.47B+19.6%
Q4 FY2025Dec 31, 2025$2.58B-61.9%
Q3 FY2025Sep 30, 2025$2.32B+8.9%
Q2 FY2025Jun 30, 2025$2.13B+9.4%
Q1 FY2025Mar 31, 2025$2.07B+6.6%
Q4 FY2024Dec 31, 2024$6.77B+251.5%
Q3 FY2024Sep 30, 2024$2.13B+23.6%
Q2 FY2024Jun 30, 2024$1.95B+12.4%
Q1 FY2024Mar 31, 2024$1.94B-15.4%
Q4 FY2023Dec 31, 2023$1.93B+7.7%
Q3 FY2023Sep 30, 2023$1.72B+6.8%
Q2 FY2023Jun 30, 2023$1.73B+7.7%
Q1 FY2023Mar 31, 2023$2.29B+53.1%
Q4 FY2022Dec 31, 2022$1.79B-2.0%
Q3 FY2022Sep 30, 2022$1.61B-2.8%
Q2 FY2022Jun 30, 2022$1.61B-8.9%
Q1 FY2022Mar 31, 2022$1.50B-10.2%
Q4 FY2021Dec 31, 2021$1.83B+6.7%
Q3 FY2021Sep 30, 2021$1.66B-2.6%
Q2 FY2021Jun 30, 2021$1.77B+11.7%
Q1 FY2021Mar 31, 2021$1.67B+20.9%
Q4 FY2020Dec 31, 2020$1.71B+11.0%
Q3 FY2020Sep 30, 2020$1.71B-25.3%
Q2 FY2020Jun 30, 2020$1.58B+22.5%
Q1 FY2020Mar 31, 2020$1.38B+7.0%
Q4 FY2019Dec 31, 2019$1.54B-76.3%
Q3 FY2019Sep 30, 2019$2.29B+80.2%
Q2 FY2019Jun 30, 2019$1.29B-2.3%
Q1 FY2019Mar 31, 2019$1.29B+3.6%
Q4 FY2018Dec 31, 2018$6.50B+361.3%
Q3 FY2018Sep 30, 2018$1.27B+3.3%
Q2 FY2018Jun 30, 2018$1.32B+7.6%
Q1 FY2018Mar 31, 2018$1.24B+8.9%
Q4 FY2017Dec 31, 2017$1.41B+16.5%
Q3 FY2017Sep 30, 2017$1.23B+11.0%
Q2 FY2017Jun 30, 2017$1.23B–
Q1 FY2017Mar 31, 2017$1.14B–
Q4 FY2016Dec 31, 2016$1.21B–
Q3 FY2016Sep 30, 2016$1.11B–

More AbbVie figures

See a number that looks wrong?